Background Back in 2004, following corresponding legislation in the US (Hatch Waxman Act) Israel amended their Patent Law to Provide for patent term extensions with what is known as the third amendment the Israel Patent Law. This creates a… Read More ›
SUMMARY In the case of IL 180336 to Helsinn Therapeutics (US) Inc, the Deputy Commissioner clarifies when it is reasonable for an Examiner to close the file. The case is a rarity in that Section 17c was invoked, but the Examiner’s… Read More ›
In Israel, Patent Term Extensions are available for basic patents to ensure at least 9 years of monopolistic sales from the first regulatory approval for a drug covered by the patent. The extension may be for anything up to five years. So… Read More ›
This ruling is a legal precedent concerning alleged misbehavior of Sanofi in prosecuting a second application for a second polymorph of clopidrogel-bisulphate, where Unipharm accused Sanofi of defrauding the patent office by inadequate disclosure and of unjustly obtaining a priority… Read More ›
Sometimes, companies publish the oddest press releases. Here is one that is doing the rounds on the Internet, and, with a dearth of decisions due to court recesses (and yes, I have been scratching around for things to write about… Read More ›
